PYY and obesity due to melanocortin 4 receptor deficiency: Expectedly, initial studies exploring the potential of PYY as an anti‐obesity drug focused on peripheral administration of PYY(3‐36), which effectively reduces weight gain by inhibiting food intake in rodents.135